MedTrace Logo

Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing In Gammopathy Patients

NCT02267733 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 51

Last updated 2016-08-25

No results posted yet for this study

Summary

A Pilot Study utilizing high dose trivalent influenza vaccine dose in a booster dosing schedule for patients with monoclonal gammopathies stratified by disease status

Conditions

Interventions

DRUG

Fluzone

Fluzone High-Dose will be administered with a planned booster at 30 days post initial administration

Sponsors & Collaborators

  • Yale University

    lead OTHER

Principal Investigators

  • Andrew Branagan, MD · Yale University

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-10-31
Primary Completion
2015-12-31
Completion
2015-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02267733 on ClinicalTrials.gov